AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer

AstraZeneca Plc AZN and Daiichi Sankyo DSNKY DSKYF shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine (T-DM1) in previously treated patients with HER2-positive unresectable and/or metastatic breast cancer.
Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to T-DM1.
In the key secondary endpoint analysis of overall survival for DESTINY-Breast03, Enhertu demonstrated a 36% reduction in risk of death versus T-DM1.
In both treatment arms, median OS was not yet reached after a median duration of follow-up of 28.4 months for Enhertu and 26.5 months for T-DM1.
An estimated 77.4% of patients were alive in the Enhertu arm at two years, compared to 69.9% of patients treated with T-DM1.
With the additional follow-up in DESTINY-Breast03, Enhertu also demonstrated a clinically meaningful improvement in progression-free survival (PFS) with a 22-month improvement in median PFS over T-DM1, reaffirming the statistically significant finding at the previous interim analysis.
In primary results from the DESTINY-Breast02 Phase 3 trial, Enhertu demonstrated a 64% reduction in the risk of disease progression or death in patients.
The median PFS for patients in the Enhertu arm was 17.8 months versus 6.9 months for those in the physician’s choice of treatment arm.
Enhertu also showed a 34% reduction in the risk of death compared to the physician’s treatment choice, with a median OS of 39.2 months versus 26.5 months.
Price Action: AZN shares are down 0.03% at $68.54 on the last check Wednesday.